Global Clinical Trial Market (2007 - 2010) (Key Therapeutic Categories, Country Wise Metrics & Regulatory Approval Framework)
Report Description
Clinical trials market now witness a paradigm shift. Na?ve heterogeneous patient populations in the developing nations is opening up new avenues for the clinical trials market. Developing countries also offer faster go to market which is triggering major pharmaceutical companies to direct their investment in these regions. Apart from this, stringent regulations and tight R&D budgets in the Pharma-Biotech industry are also forcing companies to move to east. This scenario has further boosted the alliances between the pharma-biotech companies and the clinical research organizations, with the latter accounting for major chunk of the trials conducted.
Today, emerging countries account for the largest share of the phase II/III (prime stages) clinical trials conducted globally with major focus on oncology, Alzheimer’s, metabolic and cardiovascular diseases. Support from the respective government bodies is one of the major factors affecting the clinical trials market. Clinical trials sponsored by the industry have a much higher share in the market as compared to government organizations.
The key players (Clinical Research Organizations) in the market include Chiltern, Omnicare, PPD, Parexel, Kendle and Quintles.
This research report categorizes the Global Clinical Trials Market on the basis of phases, indications, and study design analyzing trends in each. Each section will provide market data, market drivers, trends and opportunities, key players, and competitive outlook. This report will also provide more than 20 company profiles.
Clinical trials market now witness a paradigm shift. Na?ve heterogeneous patient populations in the developing nations is opening up new avenues for the clinical trials market. Developing countries also offer faster go to market which is triggering major pharmaceutical companies to direct their investment in these regions. Apart from this, stringent regulations and tight R&D budgets in the Pharma-Biotech industry are also forcing companies to move to east. This scenario has further boosted the alliances between the pharma-biotech companies and the clinical research organizations, with the latter accounting for major chunk of the trials conducted.
Today, emerging countries account for the largest share of the phase II/III (prime stages) clinical trials conducted globally with major focus on oncology, Alzheimer’s, metabolic and cardiovascular diseases. Support from the respective government bodies is one of the major factors affecting the clinical trials market. Clinical trials sponsored by the industry have a much higher share in the market as compared to government organizations.
The key players (Clinical Research Organizations) in the market include Chiltern, Omnicare, PPD, Parexel, Kendle and Quintles.
This research report categorizes the Global Clinical Trials Market on the basis of phases, indications, and study design analyzing trends in each. Each section will provide market data, market drivers, trends and opportunities, key players, and competitive outlook. This report will also provide more than 20 company profiles.
1 INTRODUCTION
1.1 Key Take-aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
2 EXECUTIVE SUMMARY
2.1 Overview of the Market
2.2 Key Findings
3 MARKET OVERVIEW
3.1 Market Definition
3.2 Drivers
3.2.1 Globalizing drug development activities
3.2.2 Rise in r&d investments expected to boost the clinical trials market
3.2.3 High disease prevalence in emerging countries
3.3 Restraints
3.3.1 Longer approval time for clinical trials – a cause of concern for major pharmaceutical-biotechnology players
3.4 Burning Issues
3.4.1 Out skirting boundaries of medical ethics
3.5 Winning Imperatives
3.5.1 Leveraging online resources to increase patient recruitment rates in clinical trials
3.6 Country Comparison
3.7 Industry Trends
3.7.1 Engaging clinical trials in emerging countries & low cost CRO’s prove to be compelling options in times of drug patent expiry
3.7.2 CROs leveraging the benefits of emerging markets
3.7.3 Changing CRO business models
3.7.3.1 Full service model
3.7.3.2 Hourly billing model
3.7.3.3 Full time equivalent model (FTE)
3.7.3.4 Fixed price model
3.7.4 Prevalence of preferred provider relationships
3.7.5 Shift towards patient centric clinical trials due to technical advances
3.8 Global Clinical Trials Market
3.8.1 Offshoring & outsourcing
4 CLINICAL TRIALS MARKET, BY TYPES
4.1 Introduction
4.1.1 Clinical trials market, by study phases
4.1.1.1 Preclinical studies
4.1.1.2 Phase I trials
4.1.1.3 Phase II trials
4.1.1.4 Phase I/II
4.1.1.5 Phase II/III
4.1.1.6 Phase III trials
4.1.2 Clinical trials market, by study designs
4.1.2.1 Observational studies
4.1.2.2 Interventional studies
4.1.2.3 Expanded access trials
4.1.3 Clinical trials market, by indications
5 GEOGRAPHIC ANALYSIS
5.1 North America
5.1.1 U.S.
5.1.1.1 Regulatory environment
5.1.1.2 Clinical trials registry
5.1.1.3 Government support
5.1.2 Canada
5.1.2.1 Regulatory environment
5.1.2.2 Clinical trials registry
5.1.2.3 Government support
5.2 Europe
5.2.1 UK
5.2.1.1 Regulatory environment
5.2.1.2 Clinical trials registry
5.2.1.3 Government support
5.2.2 Germany
5.2.2.1 Regulatory environment
5.2.2.2 Clinical trials registry
5.2.2.3 Government support
5.2.3 Italy
5.2.3.1 Regulatory environment
5.2.3.2 Clinical trials registry
5.2.3.3 Government support
5.2.4 France
5.2.4.1 Regulatory environment
5.2.4.2 Clinical trials registry
5.2.4.3 Support rendered by the government
5.2.5 Spain
5.2.5.1 Regulatory environment
5.2.5.2 Clinical trials registry
5.2.5.3 Government support
5.2.6 Poland
5.2.6.1 Regulatory environment
5.2.6.2 Clinical trials registry
5.2.6.3 Support rendered by the Government
5.2.7 Russia
5.2.7.1 Regulatory environment
5.2.7.2 Clinical trials registry
5.2.7.3 Support rendered by the Government
5.2.8 Turkey
5.2.8.1 Regulatory environment
5.2.8.2 Clinical trials registry
5.2.8.3 Government support
5.2.9 Ukraine
5.2.9.1 Regulatory environment
5.2.9.2 Clinical trials registry
5.2.9.3 Support rendered by the Government
5.3 Asia
5.3.1 China
5.3.1.1 Clinical trials registry
5.3.1.2 Government support
5.3.2 India
5.3.2.1 Regulatory environment
5.3.2.2 Clinical trials registry
5.3.2.3 Government support
5.3.3 South Korea
5.3.3.1 Regulatory environment
5.3.3.2 Clinical trials registry
5.3.3.3 Government support
5.4 Latin America
5.4.1 Brazil
5.4.1.1 Regulatory environment
5.4.1.2 Clinical trials registry
5.4.1.3 Government support
5.4.2 Mexico
5.4.2.1 Regulatory environment
5.4.2.2 Clinical trials registry
5.4.2.3 Government support
5.4.3 Argentina
5.4.3.1 Regulatory environment
5.4.3.2 Clinical trials registry
5.4.3.3 Government support
6 COMPETITIVE LANDSCAPE
6.1 Introduction
7 COMPANY PROFILES
7.1 AAIPHARMA SERVICES CORP.
7.1.1 Overview
7.1.2 Financials
7.1.3 Products & services
7.1.4 Strategy
7.1.5 Developments
7.2 ACCELL CLINICAL RESEARCH LLC
7.2.1 Overview
7.2.2 Financials
7.2.3 Products & services
7.2.4 Strategy
7.2.5 Developments
7.3 APTIV SOLUTIONS
7.3.1 Overview
7.3.2 Financials
7.3.3 Products & services
7.3.4 Strategy
7.3.5 Developments
7.4 CHILTERN INTERNATIONAL LIMITED
7.4.1 Overview
7.4.2 Financials
7.4.3 Products & services
7.4.4 Strategy
7.4.5 Developments
7.5 CONGENIX
7.5.1 Overview
7.5.2 Financials
7.5.3 Products & services
7.5.4 Strategy
7.5.5 Developments
7.6 COVANCE INC.
7.6.1 Overview
7.6.2 Financials
7.6.3 Products & services
7.6.4 Strategy
7.6.5 Developments
7.7 ECRON ACUNOVA LTD
7.7.1 Overview
7.7.2 Financials
7.7.3 Products & services
7.7.4 Strategy
7.7.5 Developments
7.8 EUROTRIALS
7.8.1 Overview
7.8.2 Financials
7.8.3 Products & services
7.8.4 Developments
7.9 ICON PLC
7.9.1 Overview
7.9.2 Financials
7.9.3 Products & services
7.9.4 Strategy
7.9.5 Developments
7.10 INC RESEARCH LLC
7.10.1 Overview
7.10.2 Financials
7.10.3 Products & services
7.10.4 Strategy
7.10.5 Developments
7.11 MEDPACE INC
7.11.1 Overview
7.11.2 Financials
7.11.3 Products & services
7.11.4 Strategy
7.11.5 Developments
7.12 PAREXEL INTERNATIONAL CORP
7.12.1 Overview
7.12.2 Financials
7.12.3 Products & services
7.12.4 Strategy
7.12.5 Developments
7.13 PHARMANET DEVELOPMENT GROUP
7.13.1 Overview
7.13.2 Financials
7.13.3 Products & services
7.13.4 Strategy
7.13.5 Developments
7.14 PHARMACEUTICAL PRODUCT DEVELOPMENT INC
7.14.1 Overview
7.14.2 Financials
7.14.3 Products & services
7.14.4 Strategy
7.14.5 Developments
7.15 PRA INTERNATIONAL
7.15.1 Overview
7.15.2 Financials
7.15.3 Products & services
7.15.4 Strategy
7.15.5 Developments
7.16 QUINTILES TRANSNATIONAL CORP
7.16.1 Overview
7.16.2 Financials
7.16.3 Products & services
7.16.4 Strategy
7.16.5 Developments
7.17 SIRO CLINPHARM PVT. LTD
7.17.1 Overview
7.17.2 Financials
7.17.3 Products & services
7.17.4 Strategy
7.17.5 Developments
7.18 TCG LIFESCIENCES LTD
7.18.1 Overview
7.18.2 Financials
7.18.3 Products & services
7.18.4 Strategy
7.18.5 Developments
7.19 THEOREM CLINICAL RESEARCH
7.19.1 Overview
7.19.2 Financials
7.19.3 Products & services
7.19.4 Strategy
7.19.5 Developments
1.1 Key Take-aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
2 EXECUTIVE SUMMARY
2.1 Overview of the Market
2.2 Key Findings
3 MARKET OVERVIEW
3.1 Market Definition
3.2 Drivers
3.2.1 Globalizing drug development activities
3.2.2 Rise in r&d investments expected to boost the clinical trials market
3.2.3 High disease prevalence in emerging countries
3.3 Restraints
3.3.1 Longer approval time for clinical trials – a cause of concern for major pharmaceutical-biotechnology players
3.4 Burning Issues
3.4.1 Out skirting boundaries of medical ethics
3.5 Winning Imperatives
3.5.1 Leveraging online resources to increase patient recruitment rates in clinical trials
3.6 Country Comparison
3.7 Industry Trends
3.7.1 Engaging clinical trials in emerging countries & low cost CRO’s prove to be compelling options in times of drug patent expiry
3.7.2 CROs leveraging the benefits of emerging markets
3.7.3 Changing CRO business models
3.7.3.1 Full service model
3.7.3.2 Hourly billing model
3.7.3.3 Full time equivalent model (FTE)
3.7.3.4 Fixed price model
3.7.4 Prevalence of preferred provider relationships
3.7.5 Shift towards patient centric clinical trials due to technical advances
3.8 Global Clinical Trials Market
3.8.1 Offshoring & outsourcing
4 CLINICAL TRIALS MARKET, BY TYPES
4.1 Introduction
4.1.1 Clinical trials market, by study phases
4.1.1.1 Preclinical studies
4.1.1.2 Phase I trials
4.1.1.3 Phase II trials
4.1.1.4 Phase I/II
4.1.1.5 Phase II/III
4.1.1.6 Phase III trials
4.1.2 Clinical trials market, by study designs
4.1.2.1 Observational studies
4.1.2.2 Interventional studies
4.1.2.3 Expanded access trials
4.1.3 Clinical trials market, by indications
5 GEOGRAPHIC ANALYSIS
5.1 North America
5.1.1 U.S.
5.1.1.1 Regulatory environment
5.1.1.2 Clinical trials registry
5.1.1.3 Government support
5.1.2 Canada
5.1.2.1 Regulatory environment
5.1.2.2 Clinical trials registry
5.1.2.3 Government support
5.2 Europe
5.2.1 UK
5.2.1.1 Regulatory environment
5.2.1.2 Clinical trials registry
5.2.1.3 Government support
5.2.2 Germany
5.2.2.1 Regulatory environment
5.2.2.2 Clinical trials registry
5.2.2.3 Government support
5.2.3 Italy
5.2.3.1 Regulatory environment
5.2.3.2 Clinical trials registry
5.2.3.3 Government support
5.2.4 France
5.2.4.1 Regulatory environment
5.2.4.2 Clinical trials registry
5.2.4.3 Support rendered by the government
5.2.5 Spain
5.2.5.1 Regulatory environment
5.2.5.2 Clinical trials registry
5.2.5.3 Government support
5.2.6 Poland
5.2.6.1 Regulatory environment
5.2.6.2 Clinical trials registry
5.2.6.3 Support rendered by the Government
5.2.7 Russia
5.2.7.1 Regulatory environment
5.2.7.2 Clinical trials registry
5.2.7.3 Support rendered by the Government
5.2.8 Turkey
5.2.8.1 Regulatory environment
5.2.8.2 Clinical trials registry
5.2.8.3 Government support
5.2.9 Ukraine
5.2.9.1 Regulatory environment
5.2.9.2 Clinical trials registry
5.2.9.3 Support rendered by the Government
5.3 Asia
5.3.1 China
5.3.1.1 Clinical trials registry
5.3.1.2 Government support
5.3.2 India
5.3.2.1 Regulatory environment
5.3.2.2 Clinical trials registry
5.3.2.3 Government support
5.3.3 South Korea
5.3.3.1 Regulatory environment
5.3.3.2 Clinical trials registry
5.3.3.3 Government support
5.4 Latin America
5.4.1 Brazil
5.4.1.1 Regulatory environment
5.4.1.2 Clinical trials registry
5.4.1.3 Government support
5.4.2 Mexico
5.4.2.1 Regulatory environment
5.4.2.2 Clinical trials registry
5.4.2.3 Government support
5.4.3 Argentina
5.4.3.1 Regulatory environment
5.4.3.2 Clinical trials registry
5.4.3.3 Government support
6 COMPETITIVE LANDSCAPE
6.1 Introduction
7 COMPANY PROFILES
7.1 AAIPHARMA SERVICES CORP.
7.1.1 Overview
7.1.2 Financials
7.1.3 Products & services
7.1.4 Strategy
7.1.5 Developments
7.2 ACCELL CLINICAL RESEARCH LLC
7.2.1 Overview
7.2.2 Financials
7.2.3 Products & services
7.2.4 Strategy
7.2.5 Developments
7.3 APTIV SOLUTIONS
7.3.1 Overview
7.3.2 Financials
7.3.3 Products & services
7.3.4 Strategy
7.3.5 Developments
7.4 CHILTERN INTERNATIONAL LIMITED
7.4.1 Overview
7.4.2 Financials
7.4.3 Products & services
7.4.4 Strategy
7.4.5 Developments
7.5 CONGENIX
7.5.1 Overview
7.5.2 Financials
7.5.3 Products & services
7.5.4 Strategy
7.5.5 Developments
7.6 COVANCE INC.
7.6.1 Overview
7.6.2 Financials
7.6.3 Products & services
7.6.4 Strategy
7.6.5 Developments
7.7 ECRON ACUNOVA LTD
7.7.1 Overview
7.7.2 Financials
7.7.3 Products & services
7.7.4 Strategy
7.7.5 Developments
7.8 EUROTRIALS
7.8.1 Overview
7.8.2 Financials
7.8.3 Products & services
7.8.4 Developments
7.9 ICON PLC
7.9.1 Overview
7.9.2 Financials
7.9.3 Products & services
7.9.4 Strategy
7.9.5 Developments
7.10 INC RESEARCH LLC
7.10.1 Overview
7.10.2 Financials
7.10.3 Products & services
7.10.4 Strategy
7.10.5 Developments
7.11 MEDPACE INC
7.11.1 Overview
7.11.2 Financials
7.11.3 Products & services
7.11.4 Strategy
7.11.5 Developments
7.12 PAREXEL INTERNATIONAL CORP
7.12.1 Overview
7.12.2 Financials
7.12.3 Products & services
7.12.4 Strategy
7.12.5 Developments
7.13 PHARMANET DEVELOPMENT GROUP
7.13.1 Overview
7.13.2 Financials
7.13.3 Products & services
7.13.4 Strategy
7.13.5 Developments
7.14 PHARMACEUTICAL PRODUCT DEVELOPMENT INC
7.14.1 Overview
7.14.2 Financials
7.14.3 Products & services
7.14.4 Strategy
7.14.5 Developments
7.15 PRA INTERNATIONAL
7.15.1 Overview
7.15.2 Financials
7.15.3 Products & services
7.15.4 Strategy
7.15.5 Developments
7.16 QUINTILES TRANSNATIONAL CORP
7.16.1 Overview
7.16.2 Financials
7.16.3 Products & services
7.16.4 Strategy
7.16.5 Developments
7.17 SIRO CLINPHARM PVT. LTD
7.17.1 Overview
7.17.2 Financials
7.17.3 Products & services
7.17.4 Strategy
7.17.5 Developments
7.18 TCG LIFESCIENCES LTD
7.18.1 Overview
7.18.2 Financials
7.18.3 Products & services
7.18.4 Strategy
7.18.5 Developments
7.19 THEOREM CLINICAL RESEARCH
7.19.1 Overview
7.19.2 Financials
7.19.3 Products & services
7.19.4 Strategy
7.19.5 Developments
LIST OF TABLES
1 Global Clinical Trials, by Phases, 2007 – 2010 (No. of Trials)
2 Clinical Trials Approval: Time & Authority
3 Drugs Set For Patent Expirations, 2010–2012
4 Phase I Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
5 Global Phase I Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
6 Phase II Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
7 Global Phase II Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
8 Phase I/II Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
9 Global Phase I/II Clinical Trials, by Indications, 2007 – 2010 (No. of Trials)
10 Phase II/III Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
11 Global Phase II/III Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
12 Phase III Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
13 Global Phase III Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
14 Observational Studies: Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
15 Interventional Studies: Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
16 Expanded Access: Clinical Trials, by Geography, 2007 – 2010 (No. of Trials)
17 Global Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
18 North America: Clinical Trials Market, by Countries, 2007 – 2010 (No. of Trials)
19 U.S: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
20 U.S: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
21 U.S: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
22 Cancer Funding in The U.S., by Types, 2008 – 2010 ($Million)
23 Canada: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
24 Canada: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
25 Canada: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
26 Europe: Clinical Trials Market, by Countries, 2007 – 2010 (No. of Trials)
27 UK: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
28 UK: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
29 UK: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
30 Germany: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
31 Germany: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
32 Germany: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
33 Italy: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
34 Italy: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
35 Italy: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
36 France: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
37 France: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
38 France: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
39 Spain: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
40 Spain: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
41 Spain: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
42 Poland: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
43 Poland: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
44 Poland: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
45 Russia: Clinical Trials Market by Phases, 2007 – 2010 (No. of Trials)
46 Russia: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
47 Russia: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
48 Turkey: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
49 Turkey: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
50 Turkey: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
51 Ukraine: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
52 Ukraine: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
53 Ukraine: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
54 Asia: Clinical Trials Market, by Country, 2007 – 2010 (No. of Trials)
55 China: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
56 China: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
57 China: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
58 India: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
59 India: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
60 India: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
61 South Korea: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
62 South Korea: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
63 South Korea: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
64 Latin America: Clinical Trials Market, by Country, 2007 – 2010 (No. of Trials)
65 Brazil: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
66 Brazil: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
67 Brazil: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
68 Mexico: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
69 Mexico: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
70 Mexico: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
71 Argentina: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
72 Argentina: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
73 Argentina: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
74 New Approvals, 2008 – 2010
75 Expansions, 2008 – 2011
76 New Trials, 2007 – 2011
77 Collaborations & Partnerships, 2008 – 2011
78 Mergers & Acquisitions, 2007 – 2011
79 Chiltern: Total Revenue, 2008 – 2010 ($Million)
80 Covance Inc: Total Revenue, 2008 – 2010 ($Million)
81 Covance Inc.: Total Revenue, by Country, 2008 – 2010 ($Million)
82 Covance Inc: Total Revenue, by Segments, 2008 – 2010 ($Million)
83 Icon Plc: Total Revenue, 2008 – 2010 ($Million)
84 Icon Plc: Total Revenue, by Geography, 2008 – 2010 ($Million)
85 Icon Plc: Total Revenue, by Segments, 2008 – 2010 ($Million)
86 Parexel International Corporation: Total Revenue, by Geography, 2008 – 2010 ($Million)
87 Parexel International Corporation: Total Revenue, by Segments, 2008 – 2010 ($Million)
88 Pharmaceutical Product Development Inc: Total Revenue, 2008 – 2010 ($Million)
89 Pharmaceutical Product Development Inc: Total Revenue, by Country, 2008 – 2010 ($Million)
90 Pharmaceutical Product Development Inc: Total Revenue, by Segments, 2008 – 2010 ($Million)
91 Theorem Clinical Research: Total Revenue, 2008 – 2010 ($Million)
92 Theorem Clinical Research: Total Revenue, by Country, 2008 – 2010 ($Million)
93 Theorem Clinical Research: Total Revenue, by Segments, 2008 – 2010 ($Million)
1 Global Clinical Trials, by Phases, 2007 – 2010 (No. of Trials)
2 Clinical Trials Approval: Time & Authority
3 Drugs Set For Patent Expirations, 2010–2012
4 Phase I Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
5 Global Phase I Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
6 Phase II Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
7 Global Phase II Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
8 Phase I/II Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
9 Global Phase I/II Clinical Trials, by Indications, 2007 – 2010 (No. of Trials)
10 Phase II/III Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
11 Global Phase II/III Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
12 Phase III Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
13 Global Phase III Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
14 Observational Studies: Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
15 Interventional Studies: Clinical Trials Market, by Geography, 2007 – 2010 (No. of Trials)
16 Expanded Access: Clinical Trials, by Geography, 2007 – 2010 (No. of Trials)
17 Global Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
18 North America: Clinical Trials Market, by Countries, 2007 – 2010 (No. of Trials)
19 U.S: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
20 U.S: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
21 U.S: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
22 Cancer Funding in The U.S., by Types, 2008 – 2010 ($Million)
23 Canada: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
24 Canada: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
25 Canada: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
26 Europe: Clinical Trials Market, by Countries, 2007 – 2010 (No. of Trials)
27 UK: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
28 UK: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
29 UK: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
30 Germany: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
31 Germany: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
32 Germany: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
33 Italy: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
34 Italy: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
35 Italy: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
36 France: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
37 France: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
38 France: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
39 Spain: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
40 Spain: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
41 Spain: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
42 Poland: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
43 Poland: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
44 Poland: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
45 Russia: Clinical Trials Market by Phases, 2007 – 2010 (No. of Trials)
46 Russia: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
47 Russia: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
48 Turkey: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
49 Turkey: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
50 Turkey: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
51 Ukraine: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
52 Ukraine: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
53 Ukraine: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
54 Asia: Clinical Trials Market, by Country, 2007 – 2010 (No. of Trials)
55 China: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
56 China: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
57 China: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
58 India: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
59 India: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
60 India: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
61 South Korea: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
62 South Korea: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
63 South Korea: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
64 Latin America: Clinical Trials Market, by Country, 2007 – 2010 (No. of Trials)
65 Brazil: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
66 Brazil: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
67 Brazil: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
68 Mexico: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
69 Mexico: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
70 Mexico: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
71 Argentina: Clinical Trials Market, by Phases, 2007 – 2010 (No. of Trials)
72 Argentina: Clinical Trials Market, by Study Designs, 2007 – 2010 (No. of Trials)
73 Argentina: Clinical Trials Market, by Indications, 2007 – 2010 (No. of Trials)
74 New Approvals, 2008 – 2010
75 Expansions, 2008 – 2011
76 New Trials, 2007 – 2011
77 Collaborations & Partnerships, 2008 – 2011
78 Mergers & Acquisitions, 2007 – 2011
79 Chiltern: Total Revenue, 2008 – 2010 ($Million)
80 Covance Inc: Total Revenue, 2008 – 2010 ($Million)
81 Covance Inc.: Total Revenue, by Country, 2008 – 2010 ($Million)
82 Covance Inc: Total Revenue, by Segments, 2008 – 2010 ($Million)
83 Icon Plc: Total Revenue, 2008 – 2010 ($Million)
84 Icon Plc: Total Revenue, by Geography, 2008 – 2010 ($Million)
85 Icon Plc: Total Revenue, by Segments, 2008 – 2010 ($Million)
86 Parexel International Corporation: Total Revenue, by Geography, 2008 – 2010 ($Million)
87 Parexel International Corporation: Total Revenue, by Segments, 2008 – 2010 ($Million)
88 Pharmaceutical Product Development Inc: Total Revenue, 2008 – 2010 ($Million)
89 Pharmaceutical Product Development Inc: Total Revenue, by Country, 2008 – 2010 ($Million)
90 Pharmaceutical Product Development Inc: Total Revenue, by Segments, 2008 – 2010 ($Million)
91 Theorem Clinical Research: Total Revenue, 2008 – 2010 ($Million)
92 Theorem Clinical Research: Total Revenue, by Country, 2008 – 2010 ($Million)
93 Theorem Clinical Research: Total Revenue, by Segments, 2008 – 2010 ($Million)
LIST OF FIGURES
1 Country Wise Parametric Comparison
2 Cost of Clinical Trials, by Country
3 U.S: Clinical Trials Regulatory Process
4 Canada: Clinical Trials Regulatory Process
5 UK: Clinical Trials Regulatory Process
6 Germany: Clinical Trials Regulatory Process
7 Italy: Clinical Trials Regulatory Process
8 France: Clinical Trials Regulatory Process
9 Spain: Clinical Trials Regulatory Process
10 Poland: Clinical Trials Regulatory Process
11 Russia: Clinical Trials Regulatory Process
12 Turkey: Clinical Trials Regulatory Process
13 Ukraine: Clinical Trials Regulatory Process
14 China: Clinical Trials Regulatory Process
15 India: Clinical Trials Regulatory Process
16 South Korea: Clinical Trials Regulatory Process
17 Brazil: Clinical Trials Regulatory Process
18 Mexico: Clinical Trials Regulatory Process
19 Argentina: Clinical Trials Regulatory Process
20 Major Growth Strategies In Global Clinical Trials Market, January 2008 – July 2011
1 Country Wise Parametric Comparison
2 Cost of Clinical Trials, by Country
3 U.S: Clinical Trials Regulatory Process
4 Canada: Clinical Trials Regulatory Process
5 UK: Clinical Trials Regulatory Process
6 Germany: Clinical Trials Regulatory Process
7 Italy: Clinical Trials Regulatory Process
8 France: Clinical Trials Regulatory Process
9 Spain: Clinical Trials Regulatory Process
10 Poland: Clinical Trials Regulatory Process
11 Russia: Clinical Trials Regulatory Process
12 Turkey: Clinical Trials Regulatory Process
13 Ukraine: Clinical Trials Regulatory Process
14 China: Clinical Trials Regulatory Process
15 India: Clinical Trials Regulatory Process
16 South Korea: Clinical Trials Regulatory Process
17 Brazil: Clinical Trials Regulatory Process
18 Mexico: Clinical Trials Regulatory Process
19 Argentina: Clinical Trials Regulatory Process
20 Major Growth Strategies In Global Clinical Trials Market, January 2008 – July 2011
